Natco Pharma has announced the commercial launch of its brand - BENDIT- Bendamustine, a novel agent in the treatment of Chronic Lymphocytic Leukemia (CLL), mostly seen in the elderly people.
Bendamustine is a unique hybrid cytotoxic, which is mechanistically distinct from the existing options. Response rates to Bendamustine are reported to be high and durable and the therapy is seen as a superior and tolerable first line option in the treatment of CLL.
Source :www.biginfotech.in
Bendamustine is a unique hybrid cytotoxic, which is mechanistically distinct from the existing options. Response rates to Bendamustine are reported to be high and durable and the therapy is seen as a superior and tolerable first line option in the treatment of CLL.
Source :www.biginfotech.in
No comments:
Post a Comment